Shani Eli 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 8, 2022

Form 4

Period: 2022-03-04

EVP,Global Marketing&Portfolio

Transactions

Award
Restricted Share Units
2022-03-04+80,428→ 80,428 total
→ Ordinary Shares (80,428 underlying)
Exercise/Conversion
Ordinary Shares
2022-03-04+3,173→ 12,264 total
Exercise/Conversion
Restricted Share Units
2022-03-04−3,173→ 3,173 total
→ Ordinary Shares (3,173 underlying)
Exercise/Conversion
Ordinary Shares
2022-03-05+5,896→ 18,160 total
Exercise/Conversion
Restricted Share Units
2022-03-05−5,896→ 17,690 total
→ Ordinary Shares (5,896 underlying)

Footnotes (5)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Restricted share units were granted on March 4, 2019, with 3,173 vesting on each of March 4 2022 and March 4, 2023.
[F4]Restricted share units were granted on March 4, 2022, with 20,107 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
[F5]Restricted share units were granted on March 5, 2021, with 5,896 having vested on March 5, 2022, 5,896 vesting on each of March 5, 2023 and March 5, 2024, and 5,898 vesting on March 5, 2025.

Documents

1 file